We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Small Molecules
We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Priothera is leading the way in developing mocravimod, a S1P receptor modulator as an adjunctive immune therapy to allo-HSCT.
S1P receptor modulators largely reduce the egress of T-cell subsets from lymphatic tissues and are thereby suggested to inhibit graft-versus-host disease (GvHD) while at the same time enhancing graft-versus-leukemia benefits in patients receiving allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Priothera is developing mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT. Mocravimod has been studied in pre-clinical stem cell transplantation models and has shown a survival benefit. In addition, mocravimod was safe and well tolerated and showed efficacy in patients with hematological malignancies undergoing allo-HSCT.